Abstract
IntroductionRecent cardiovascular outcomes trials have demonstrated that glucagon-like peptide 1 receptor agonist (GLP-1RA) decreases the incidence of major adverse cardiovascular events (MACEs) in individuals with type 2 diabetes mellitus (T2DM)....
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have